COSM: COSM: Cosmos Health launches premium Korean collagen skincare; US DTC sales live

AI Summary

Cosmos Health (NASDAQ: COSM) announced entry into the global skincare market with a premium Korean-developed collagen-based line and says direct-to-consumer sales have been live in the U.S. for over a month as it plans a multi-brand rollout. The company highlights the $163B global skincare market and EU GMP-certified manufacturing via subsidiary Cana Laboratories, but disclosed no sales figures, financial guidance or expected revenue contribution from the launch.

Positives

U.S. direct-to-consumer sales of the new skincare line have been live for over one month
Targeting premium, high-growth segment of the ~$163B global skincare market
Has EU GMP-certified manufacturing capability through Cana Laboratories

Negatives

No revenue, unit-sales, pricing or growth metrics disclosed for the new brand
Launch is early-stage (just over one month of sales); traction and repeat purchase rates unknown
Company provided no guidance or timeline for revenue contribution from the skincare business